ClinicalTrials.gg
CompletedNCT07655180LIBERTYUpdated Oct 14, 2026

Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine

A Phase 3 interventional study of COVID-19 mRNA vaccine and VYD2311 in COVID-19, sponsored by Invivyd, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Invivyd, Inc. · Phase 3, Interventional, and Prevention

Updated Oct 14, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing mRNA COVID-19 Vaccine in COVID-19 — 3 open to participants now, 3 under way, none of them phase 3. mRNA COVID-19 Vaccine · COVID-19.

Enrollment
5th of 12
210 · median 157
Started
2026
the only one that year
Phase 3
4 of 12
none open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Invivyd, Inc.

Among the 12 studies testing mRNA COVID-19 Vaccine in COVID-19, this one is the 5th largest by enrollment, is the only one that started in 2026, is one of 4 in phase 3, and was the 12th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

3 of the 12 studies testing mRNA COVID-19 Vaccine in COVID-19 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About mRNA COVID-19 Vaccine

mRNA COVID-19 Vaccine: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing mRNA COVID-19 Vaccine in COVID-19, or all of them as a file.
02

Study summary

The main purposes of this research study are to measure the safety (whether it causes any side effects), tolerability (if it does cause any side effects, how well your body is able to handle them), and reactions, both local at the injection site and systemic, that may occur in the body after receiving VYD2311, or a COVID-19 vaccine, or a combination of VYD2311 and a COVID-19 vaccine in healthy participants. This research study will measure the amount of serum virus neutralizing antibodies produced in the blood (antibodies that block a virus from infecting cells) and pharmacokinetics of VYD2311 compared to a COVID-19 vaccine, when each is administered alone or concurrently. Pharmacokinetics is the study of how a drug moves through the body, including how it is absorbed (taken into the body), distributed (spread throughout the body), metabolized (broken down in the body), and eliminated (removed from the body), and how the body affects the drug.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • COVID-19
  • COVID
  • mAb
  • antibody
  • VYD2311
  • LIBERTY
  • Invivyd
  • vaccine
  • SARS-CoV-2 Monocloncal antibody
04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is a healthy adult male or female aged 18 to 49 years, inclusive, weighing at least 40 kg at the time of Screening
  2. Has a (BMI) 18.0 to 32.0 mg/kg2, inclusive.
  3. Is in good health, with no abnormalities as determined by the Investigator based on medical history, physical exam, vital signs, and per study site standard operating procedures.

Exclusion criteria

Exclusion Criteria:

  1. Prior receipt of VYD2311 or pemivibart (VYD222).
  2. Prior receipt of a COVID-19 vaccine within 6 months before Day 0 and prior receipt of a non-COVID-19 vaccine within 28 days before Day 0.
  3. Prior receipt of convalescent plasma, a mAb to SARS-CoV-2 (other than VYD2311 or pemivibart), or IVIG within 6 months before Day 0.
  4. Prior known or suspected SARS-CoV-2 infection within 6 months before Day 0.
  5. Tests positive for current SARS-CoV-2 infection by RAT or local nucleic acid amplification test (eg, RT-PCR) on Day 0.
  6. Exposure to someone with known or suspected SARS-CoV-2 infection in the 5 days before Day 0.
  7. Is acutely ill, including symptoms suggestive of SARS-CoV-2 infection, in the opinion of the investigator or has a fever ≥38oC (≥100.4oF) within 14 days of Day 0.
  8. Any chronic or significant medical condition that, in the opinion of the Investigator, might compromise participant safety or interfere with evaluation of the study drug or interpretation of participant safety or study results.

NOTE: The above information is not intended to contain all considerations relevant to a participant's potential eligibility in the clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
210 participants (actual)

Study arms

  • Active comparator
    Treatment Arm 1: A COVID-19 vaccine and Placebo administered as 2 separate IM injections

    Treatment Arm 1: A COVID-19 vaccine administered by IM injection and placebo administered by IM injection in separate locations

    Drug: COVID-19 mRNA vaccine · Drug: Placebo (Normal Saline)

  • Active comparator
    Treatment Arm 2: VYD2311 and Placebo administered as 2 separate IM injections

    Treatment Arm 2: VYD2311 250 mg administered by IM injection and placebo administered by IM injection in separate locations

    Drug: VYD2311 · Drug: Placebo (Normal Saline)

  • Active comparator
    Treatment Arm 3: VYD2311 and COVID-19 vaccine administered as 2 separate IM injections

    Treatment Arm 3: VYD2311 250 mg and a COVID-19 vaccine adminstered as two IM injections in separate locations

    Drug: COVID-19 mRNA vaccine · Drug: VYD2311

Interventions

  • A one-time dose of COVID-19 mRNA vaccine will be administered by intramuscular injection.

  • A one-time dose of VYD2311 250mg will be administered by intramuscular injection.

  • DrugPlacebo (Normal Saline)

    A one-time dose of normal saline (placebo) administered by intramuscular injection.

06

What researchers measure

Primary outcomes

  1. Assessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through day 6

    Time frame: Through 6 days after dose

  2. Assessment of systemic reactions solicited via e-diary through day 6

    To compare the systemic reaction of VYD2311 (study drug) with a COVID-19 vaccine when administered alone or concurrently in healthy adults. E-diaries will solicit participant reported systemic reactions including vomiting, fever, diarrhea, headache, fatigue, chills, myalgia, and arthralgia.

    Time frame: Through 6 days after dose

Secondary outcomes

  1. Assessment of safety based on treatment emergent adverse events, injection site reactions, and hypersensitivity reactions through day 56

    Time frame: Through 56 days after dose

  2. sVNA titers (VYD2311 serum concentration/variant IC50) against relevant SARS-CoV-2 variants through Day 56

    Time frame: Through 56 days after dose

  3. Serum concentrations of VYD2311 through Day 56

    Time frame: Through 56 days after dose

07

Study locations

1 site
  • Invivyd Investigative Site
    Overland Park, Kansas 66212, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2026 to primary completion in Aug 2026, 2 months.

Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 2 months is below that.

Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 17, 2026
StartActual
Jun 8, 2026
Primary completionActual
Aug 15, 2026
CompletionActual
Aug 15, 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Recruiting→Completed
    + 4 other changes: verification date, date precision, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07655180
Lead sponsor
Invivyd, Inc.
Responsible party
Sponsor
First posted
Jun 17, 2026
Start date
Jun 8, 2026
Primary completion
Aug 15, 2026
Completion
Aug 15, 2026
Last update
Oct 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: mRNA COVID-19 Vaccine · Ibramvibart

Start the discussion